US okays protocol for PNT (Pneumatic Trabeculoplasty) glaucoma therapy study:
This article was originally published in Clinica
Coronado Industries is pressing ahead with efforts to gather data to support a US marketing application for its non-invasive pneumatic device for treating glaucoma, after receiving FDA approval for its study protocol. The Pneumatic Trabeculoplasty (PNT) device, which is already CE-marked for sale in Europe, works by applying suction to the eye for two minutes to reduce intraocular pressure. The Fountain Hills, Arizona firm says it is working with Novartis on an agreement covering exclusive global licensing and distribution rights to the product.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.